{"disease":{"id":"resectable-hepatocellular-carcinoma","name":"resectable hepatocellular carcinoma"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05667064","title":"Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07204327","title":"Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1136,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT04947956","title":"Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT04770896","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":557,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07065786","title":"A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06788353","title":"Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06739317","title":"SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06796803","title":"Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT01015833","title":"Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06117891","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01176604","title":"Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01004978","title":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05263219","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":230,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06593964","title":"TACE With Thermosensitive Nanogel Versus Embosphere for HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT03186898","title":"Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06315101","title":"Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Guangzhou University of Chinese Medicine","has_results":false},{"nct_id":"NCT07227012","title":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05168163","title":"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06503250","title":"A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06360042","title":"Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT02379377","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06909708","title":"SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","phase":"NA","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06485466","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":101,"lead_sponsor_name":"Guohui Xu","has_results":false},{"nct_id":"NCT07064681","title":"The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07351513","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT03044587","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06013657","title":"Surgical Resection for Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Dr Cipto Mangunkusumo General Hospital","has_results":false},{"nct_id":"NCT03942328","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03823144","title":"Intravital Microscopy in Human Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04401800","title":"Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07110233","title":"Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07446257","title":"THIO and Cadonilimab in Resectable Hepatocellular Carcinoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06280313","title":"Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Zhiyong Huang","has_results":false},{"nct_id":"NCT05519410","title":"Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05582278","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Wen Li","has_results":false},{"nct_id":"NCT06896396","title":"Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Zhiyong Huang","has_results":false},{"nct_id":"NCT05319431","title":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05578430","title":"AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04387695","title":"SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT05042336","title":"The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06143579","title":"A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05135364","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Yue Han","has_results":false},{"nct_id":"NCT05507632","title":"Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03896646","title":"Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04175912","title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06310590","title":"Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Chengdu New Radiomedicine Technology Co. LTD.","has_results":false},{"nct_id":"NCT01900002","title":"Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}